The product is a generic therapeutic equivalent version of the Reference Listed Drug (RLD) from Mallinckrodt Pharmaceuticals Ireland Ltd. Shares of Caplin Point Laboratories Ltd ended at ₹1,961.00, down by ₹2.05, or 0.10%, on the BSE.
The product is a generic therapeutic equivalent version of the Reference Listed Drug (RLD) from Mallinckrodt Pharmaceuticals Ireland Ltd. Shares of Caplin Point Laboratories Ltd ended at ₹1,961.00, down by ₹2.05, or 0.10%, on the BSE.